Aytu BioPharma (USA: $AYTU) Trading For Less Than $1 Dollar! 🧬Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
Aytubiopharma
AYTU All Time Low | Fast Track Designation form FDA todayAYTU Aytu BioPharma announced today that the FDA has granted Fast Track designation to AR101, a protein kinase inhibitor, for the treatment of patients with Vascular Ehlers-Danlos Syndrome.
After the bullish news, AYTU stock hit the all time low level.
52 Week Range 0.76 - 7.20
LADENBURG THALM has a price target of $14.50 for the stock.
I think a reversal is imminent.
My price target is $5.25.
Looking forward to read your opinion about it.
AYTU BioPharma (NASDAQ: $AYTU) Oversold & Ready To Reverse 🧬Aytu BioPharma: Helping children get off to a healthier start and a better life.
Aytu is committed to improving the health of all children. We’re developing a portfolio of products to help children be their best and now expanding into ADHD. Our Adult and consumer health products remain an important part of our heritage, while we study COVID-19 treatments and invest in breakthroughs for rare diseases. Follow us on our journey.
A growing portfolio:
ADHD
PEDIATRICS
ADULT HEALTH
CONSUMER HEALTH